Bioxiness is developing a novel class of antimicrobial drugs. These drugs are small molecules engineered for enhanced bacteria uptake. These compounds are being developed to inhibit previously underexplored crucial bacterial enzyme-targets. Bioxiness’ compounds have the potential to be used as systemic antimicrobial drugs in multiple clinical areas.
The breadth and scope of Bioxiness’ scientific applications enable it to target a broad range of bacterial infections. Unlike many other antibiotics, Bioxiness molecules are a novel class of compounds that are targeted towards crucial steps within the bacterial life cycle. Because these are target-specific new molecules without prior use, the possibility for bacteria to survive and develop resistance is minimal.